Biotech, cancer, clinical trials

Oncothyreon Shows Long-Lasting Effect

Luke Timmerman 8/3/09

Oncothyreon (NASDAQ: ONTY), the Seattle-based developer of cancer treatments, said today its Stimuvax therapy showed a long-lasting response and was well-tolerated in a long-term follow-up study. Ten of the 16 patients with non-small cell lung cancer, who were followed two to 8.2 years, were still alive as of April with no evidence of their disease spreading after they got Stimuvax. The treatment, being co-developed with Germany-based Merck KGaA, was well-tolerated during long-term use, researchers said. Data were presented Saturday at the World Conference on Lung Cancer in San Francisco.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.